Zymeworks Inc (ZYME):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zymeworks Inc (ZYME) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8038
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zymeworks Inc (Zymeworks) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of biotherapeutics for the treatment of cancer, autoimmune and inflammatory diseases. Its pipeline products include ZW25 and ZW49, novel bispecific antibodies used for the removal of HER2 protein from the cell surface in patients with gastric, breast, and ovarian cancers. Zymeworks’ proprietary therapeutic platforms and its fully-integrated drug development engine ZymeCAD, provide the compatibility to engineer and develop highly-differentiated protein-based drugs candidates.The company is developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. The company has operations in Canada and the US. Zymeworks is headquartered in Vancouver, British Columbia, Canada.

Zymeworks Inc (ZYME) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zymeworks Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zymeworks Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Zymeworks Raises USD61.5 Million in Series A Financing 12
Zymeworks Secures USD23.98 Million in Venture Funding 14
Zymeworks Raises USD4 Million in Venture Financing 15
Zymeworks Raises US$11 Million In Venture Financing 16
Partnerships 17
ImClone Systems Enters Licensing Agreement with Zymeworks 17
Zymeworks Enters into Research Agreement with University of Victoria and BC Cancer Agency 18
Applied BioMath Extends Partnership with Zymeworks 19
Zymeworks Enters into Agreement with Kairos Therapeutics 20
ProBioGen Enters into Agreement with Zymeworks 21
Zymeworks Enters into Research Agreement with University of California, Los Angeles 22
National Research Council Enters into Co-Development Agreement with Zymeworks for Cancer 23
Licensing Agreements 24
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 24
Janssen Biotech Enters into Licensing Agreement with Zymeworks 25
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 26
Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 27
Zymeworks Enters into Licensing Agreement with Innovative Targeting Solutions 28
Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 29
Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 30
Zymeworks Enters into Licensing Agreement with Selexis 31
Celgene Exercises Licensing Agreement with Zymeworks for Bi-Specific Antibody 32
Zymeworks Extends Licensing Agreement with Merck 33
Zymeworks Expands Licensing Agreement with Eli Lilly 34
Zymeworks Enters into Licensing with Agreement with Lilly 35
Equity Offering 36
Zymeworks Raises USD97.8 Million in Public Offering of Share 36
Zymeworks Announces Underwriters Exercise of Over-Allotment Option in IPO 38
Zymeworks Raises USD1.8 Million in Private Placement of Shares 40
Zymeworks Raises USD8.6 Million in Private Placement of Shares 41
Zymeworks Completes Private Placement of Shares for USD17.3 Million 42
Acquisition 43
Zymeworks Acquires Remaining 80.01% Stake in Kairos Therapeutics for USD24.8 Million 43
Zymeworks Acquires 19.99% Stake in Kairos Therapeutics for USD3.6 Million 44
Zymeworks Inc – Key Competitors 45
Zymeworks Inc – Key Employees 46
Zymeworks Inc – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Financial Announcements 48
Aug 01, 2018: Zymeworks reports financial results for the second quarter of 2018 48
May 01, 2018: Zymeworks Reports 2018 First Quarter Financial Results 50
Mar 14, 2018: Zymeworks Reports 2017 Year-End Financial Results 51
Nov 08, 2017: Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update 52
Aug 08, 2017: Zymeworks Reports Second Quarter 2017 Financial Results 53
May 15, 2017: Zymeworks Reports First Quarter 2017 Financial Results 54
Corporate Communications 55
Sep 19, 2018: Zymeworks appoints Anthony Polverino as executive vice president of early development and Chief Scientific Officer 55
Jun 07, 2018: Zymeworks appoints Ali Tehrani and Nick Bedford as board directors 56
Feb 14, 2017: Zymeworks Appoints Dr. Kenneth Hillan and Hollings Renton to its Board of Directors 57
Product News 58
Jan 05, 2017: Zymeworks Announces the Successful Achievement of a Research Milestone with Lilly in Bispecific Antibody Collaboration 58
Clinical Trials 59
Mar 14, 2018: Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Zymeworks Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zymeworks Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zymeworks Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zymeworks Raises USD61.5 Million in Series A Financing 12
Zymeworks Secures USD23.98 Million in Venture Funding 14
Zymeworks Raises USD4 Million in Venture Financing 15
Zymeworks Raises US$11 Million In Venture Financing 16
ImClone Systems Enters Licensing Agreement with Zymeworks 17
Zymeworks Enters into Research Agreement with University of Victoria and BC Cancer Agency 18
Applied BioMath Extends Partnership with Zymeworks 19
Zymeworks Enters into Agreement with Kairos Therapeutics 20
ProBioGen Enters into Agreement with Zymeworks 21
Zymeworks Enters into Research Agreement with University of California, Los Angeles 22
National Research Council Enters into Co-Development Agreement with Zymeworks for Cancer 23
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 24
Janssen Biotech Enters into Licensing Agreement with Zymeworks 25
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 26
Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 27
Zymeworks Enters into Licensing Agreement with Innovative Targeting Solutions 28
Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 29
Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 30
Zymeworks Enters into Licensing Agreement with Selexis 31
Celgene Exercises Licensing Agreement with Zymeworks for Bi-Specific Antibody 32
Zymeworks Extends Licensing Agreement with Merck 33
Zymeworks Expands Licensing Agreement with Eli Lilly 34
Zymeworks Enters into Licensing with Agreement with Lilly 35
Zymeworks Raises USD97.8 Million in Public Offering of Share 36
Zymeworks Announces Underwriters Exercise of Over-Allotment Option in IPO 38
Zymeworks Raises USD1.8 Million in Private Placement of Shares 40
Zymeworks Raises USD8.6 Million in Private Placement of Shares 41
Zymeworks Completes Private Placement of Shares for USD17.3 Million 42
Zymeworks Acquires Remaining 80.01% Stake in Kairos Therapeutics for USD24.8 Million 43
Zymeworks Acquires 19.99% Stake in Kairos Therapeutics for USD3.6 Million 44
Zymeworks Inc, Key Competitors 45
Zymeworks Inc, Key Employees 46
Zymeworks Inc, Subsidiaries 47

List of Figures
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Zymeworks Inc (ZYME):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • IXICO Plc (IXI)-製薬・医療分野:企業M&A・提携分析
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints. The company provides clinical trial services for assessing the safety and efficacy of drugs. Its product portfolio includes web-based platform to transf …
  • Riyad Bank:企業の戦略・SWOT・財務分析
    Riyad Bank - Strategy, SWOT and Corporate Finance Report Summary Riyad Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Starwood Property Trust Inc:企業のM&A・事業提携・投資動向
    Starwood Property Trust Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Starwood Property Trust Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Fortis Healthcare Ltd (FORTIS):企業の財務・戦略的SWOT分析
    Fortis Healthcare Ltd (FORTIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Edgemont Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Edgemont Pharmaceuticals LLC (Edgemont) is a pharmaceutical company that develops, acquires, and markets products for the treatment of psychiatric disorders. The company focuses on the development of novel drug formulations and therapies in the field of neuroscience. Its portfolio of product …
  • University of Copenhagen:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Copenhagen (UCPH) is a university and research institution that offers educational and research programs and services. The university’ services include graduate and undergraduate courses, research programs, master's programs, continuing education services, online courses, inter …
  • Oil-Dri Corporation of America (ODC):企業の財務・戦略的SWOT分析
    Summary Oil-Dri Corporation of America (Oil-Dri) is a manufacturer and supplier of sorbent products. The company offers granular clay absorbents, universal absorbent products, oil only absorbents, haz mat, socks and boom, spill kits, sweeping compounds, and secondary containment products. Its univer …
  • Hanwha Corp (000880):企業の財務・戦略的SWOT分析
    Hanwha Corp (000880) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Apex Healthcare Berhad (AHEALTH):企業の財務・戦略的SWOT分析
    Apex Healthcare Berhad (AHEALTH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Smurfit Kappa Group plc:企業の戦略・SWOT・財務情報
    Smurfit Kappa Group plc - Strategy, SWOT and Corporate Finance Report Summary Smurfit Kappa Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • ORBCOMM Inc (ORBC):企業の財務・戦略的SWOT分析
    ORBCOMM Inc (ORBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Esselte Corporation:企業の戦略・SWOT・財務分析
    Esselte Corporation - Strategy, SWOT and Corporate Finance Report Summary Esselte Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Copenhagen Infrastructure Partners KS:電力:M&Aディール及び事業提携情報
    Summary Copenhagen Infrastructure Partners KS (CIP) is a fund management service provider. The company provides structuring, executing and managing investments within energy infrastructure. It invests in energy infrastructure assets including offshore wind, onshore wind, offshore power transmission, …
  • Odakyu Electric Railway Co., Ltd. (9007):企業の財務・戦略的SWOT分析
    Odakyu Electric Railway Co., Ltd. (9007) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Relievant MedSystems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Relievant MedSystems Inc (Relievant) is a medical device company developing new minimally-invasive solutions for the treatment of chronic low back pain (CLBP). The company's Intracept system, a minimally invasive procedure uses radiofrequency energy delivered through a small access tube into …
  • Southwest Gas Holdings, Inc.:企業の戦略・SWOT・財務分析
    Southwest Gas Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Southwest Gas Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • R-Biopharm AG:医療機器:M&Aディール及び事業提携情報
    Summary R-Biopharm AG (R-Biopharm), a subsidiary of Rohm Gmbh & Co KG, is a developer of test solutions for clinical diagnostics and food and feed analysis. The company offers test systems in the areas of infectological stool diagnostics, serological infection and allergy diagnostics for clinical di …
  • Furukawa Electric Co Ltd (FUWAY):企業の財務・戦略的SWOT分析
    Furukawa Electric Co Ltd (FUWAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Mr.Sub:企業の戦略・SWOT・財務情報
    Mr.Sub - Strategy, SWOT and Corporate Finance Report Summary Mr.Sub - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Virtus Investment Partners, Inc.:企業の戦略・SWOT・財務分析
    Virtus Investment Partners, Inc. - Strategy, SWOT and Corporate Finance Report Summary Virtus Investment Partners, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆